Phospholipids
Sanofi-aventis
1968 Items
2019-09-19
- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Clinical Pharmacology
Hepatoprotective agent
Indications
- chronic hepatitis;
- cirrhosis of the liver;
- fatty degeneration of the liver of various etiologies;
- toxic liver damage;
- alcoholic hepatitis;
- abnormal liver function in other somatic diseases;
- pregnancy toxicosis;
- prevention of recurrence of gallstones formation;
- psoriasis (as a means of adjuvant therapy);
- radiation syndrome.
Composition
1 caps contains phospholipids from soybeans, containing 76% (3-sn-phosphatidyl) choline (synonyms - essential phospholipids, EPL®) 300 mg
Excipients: solid fat - 57.000 mg, soy bean oil - 36.000 mg, hydrogenated castor oil - 1.600 mg, ethanol 96% - 8.100 mg, ethyl vanillin - 1.500 mg, 4-methoxyacetophenone - 0.800 mg, α-tocopherol - 0.750 mg.
The composition of the capsule: gelatin - 67.945 mg, purified water - 11.495 mg, titanium dioxide (E171) - 0.830 mg, iron dye yellow oxide (E172) - 2.075 mg, iron dye black oxide (E172) - 0.332 mg, iron dye red oxide ( E172) - 0.198 mg, sodium lauryl sulfate - 0.125 mg.
Phospholipids is marketed under different brands and generic names, and comes in different dosage forms:
| Brand name | Manufacturer | Country | Dosage form |
|---|---|---|---|
| Essentiale Forte N | Sanofi-aventis | France | capsules |
| Essentiale N | Sanofi-aventis | France | solution |
| Rezalut Pro | Berlin-Chemie/Menarini | Germany | capsules |
No customer reviews for the moment.
Dosage and Administration
Orally, in acute dysentery for adults in 1-2 days - 1 g 6 times a day, in 3-4 days - 1 g 4 times a day, in 5-6 days - 1 g 3 times a day. The average course dose is 25-30 g. After 5-6 days, the second course of treatment is carried out: 1-2 days - 1 g 5 times a day (in the afternoon - every 4 hours, at night - in 8 hours), 3-4 days - 1 g 4 times a day (do not give at night), 5 day - 1 g 3 times a day. The total dose in the second cycle - 21 g, with a light current - 18 g.
Higher doses for adults: single - 2 g, daily - 7 g.
Children up to 3 years old - at 0.2 g / kg in 3 doses for 7 days, over 3 years old - at 0.4-0.75 g 4 times a day.
For other infections, adults in the first 2-3 days are prescribed 1-2 g every 4-6 hours, in the next 2-3 days - half the dose; children - 0.1 g / kg / day in equal doses after 4 hours with a night break, on the following days - 0.2-0.5 g every 6-8 hours.
Ftalazol treatment, if necessary, combined with the appointment of antibiotics. It is advisable to simultaneously appoint well absorbed sulfonate with Ftalazol
Adverse reactions
Allergic reactions (rash, fever), vitamin B deficiency (due to inhibition of intestinal microflora), agranulocytosis, aplastic anemia.
Contraindications
Increased individual sensitivity to sulfa drugs, diseases of the blood system, diffuse toxic goiter, kidney disease, acute hepatitis, intestinal obstruction
Drug interactions
When using Ftalazol in conjunction with other drugs, the following interactions may occur.
PAS and barbiturates: increased activity of sulfonamides.
Thioacetazone, chloramphenicol: increases the possibility of agranulocytosis.
Nitrofurans: increases the risk of anemia and methemoglobinemia.
Indirect anticoagulants: enhanced anticoagulant action.
Oxacillin: antibiotic activity is reduced.
The combined use of Ftalazol with acids and acid-reactive drugs, hexamethylenetetramine, adrenaline solution is impractical, because they are chemically incompatible.
With the combined use of Ftalazol with preparations containing PABA esters (novocaine, anestezin, dikain), the antibacterial activity of sulfanilamide is inactivated by a competitive mechanism. The effect is enhanced by antibiotics and well absorbed sulfonamides.
- Brand name: Essentiale Forte N
- Active ingredient: Phospholipids
- Dosage form: Hard gelatin capsules, brown, opaque; the contents of the capsules - oily pasty mass of yellowish-brown color.
- Manufacturer: Sanofi-aventis
- Country of Origin: France
Studies and clinical trials of Phospholipids (Click to expand)
- Characterization of Phospholipids by Electron Impact, Field Desorption and Liquid Secondary Ion Mass Spectrometry
- Mass spectrometric analysis of arachidonyl-containing phospholipids in human U937 cells
- Fast atom bombardment tandem mass spectrometric analysis of phospholipids inDrosophila melanogaster
- Electrospray ionization mass spectrometric method for the determination of cannabinoid precursors:N-acylethanolamine phospholipids (NAPEs)
- Oxidation of muscle phospholipids in relation to their fatty acid composition with emphasis on volatile compounds
- Fatty acid composition of phospholipids in epithelium and stroma of human benign prostatic hyperplasia
- Prediagnostic level of fatty acids in serum phospholipids: Ω-3 and Ω-6 fatty acids and the risk of prostate cancer
- Fatty-acid composition in serum phospholipids and risk of breast cancer: An incident case-control study in Sweden
- Liquid Chromatography/Mass Spectrometry of Phospholipids in Soybean Products Using Particle Beam and Ionspray Interfaces
- Normal-phase Liquid Chromatography Class Separation and Species Determination of Phospholipids Utilizing Electrospray Mass Spectrometry/Tandem Mass Spectrometry
- Investigation of beam-induced reactions occurring under fast-atom bombardment conditions between triethanolamine and various phospholipids
- The persistent memory effect of triethylamine in the analysis of phospholipids by liquid chromatography/mass spectrometry
- Phospholipids alter tau conformation, phosphorylation, proteolysis, and association with microtubules: Implication for tau function under normal and degenerative conditions
- Effect of acidic phospholipids on sphingosine kinase
- Syntheses of arsinolipids: non-isosteric analogues of phospholipids
- Discriminatory recognition of membrane phospholipids by lysine-49-phospholipases A2 from Trimeresurus flavoviridis venom
- Tissue Phospholipids during Human Pregnancy by 31P NMR: Myometrium, Decidua, Placenta and Fetal Membranes
- Esophageal cancer phospholipids correlated with histopathologic findings: a 31P NMR study
- Chlorophyll-derived porphyrins co-chromatograph with phospholipids in high performance liquid chromatographic separations of plant lipid classes
- The effects of phospholipids on crystallisation and crystal habit in triglycerides
- Membrane Properties of Archæal Macrocyclic Diether Phospholipids
- An Effective Fluorescent Sensor for Choline-Containing Phospholipids
- Use of stable isotope labeling technique and mass isotopomer distribution analysis of [13C]palmitate isolated from surfactant disaturated phospholipids to study surfactant in vivo kinetics in a premature infant
8 other products in the same category:
arrow_upward